$PTCT

PTC Therapeutics director Michael Schmertzler sold $158,480 in shares indirectly through Section Six Partners, L.P. The shares were sold at $63.38 to $63.95 each, with PTCT stock currently at $64.70. The company, with a $5.37B market cap, reports earnings on October 22. Analysts' price targets range from $70 to $137. PTCT reported Q2 2026 earnings of $0.92 per share on $361M revenue, exceeding expectations.

Argus lowered its target price for PTC Therapeutics (PTCT) to $61.00, maintaining a HOLD rating. The company has medium ratings for industry, management, and growth, but low ratings for safety and value.

RBC Capital reiterated its Sector Perform rating on PTC Therapeutics (PTCT) with an $85 price target, citing its strong balance sheet and early-stage pipeline. The company's Q2 2026 earnings of $0.92 per share on $361M revenue beat estimates. PTCT completed a gene therapy acquisition and raised its full-year outlook. Cantor Fitzgerald raised its price target to $137, maintaining an Overweight rating.

STEELE GLENN JR MD PHD sold 12,000 shares of PTC THERAPEUTICS, INC. (PTCT) at $65.16 ($0.78M total) on 2026-09-30 under a Rule 10b5-1 trading plan.

Cantor Fitzgerald kept its Overweight rating on PTC Therapeutics (PTCT) with a $137 price target, implying a 109.9% upside from the Sep 21 close. The firm cited PTC's acquisition of ST-920 for Fabry disease and the growing recognition of its pipeline value as reasons for the rating.

PTC THERAPEUTICS, INC. (PTCT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy – Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo

SCHMERTZLER MICHAEL sold 20,000 indirectly-held shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $67.49 ($66.58–$68.45, $1.35M total) across 4 trades over 2026-09-16 to 2026-09-17 under a Rule 10b5-1 trading plan.

Leerink Partners rated PTC Therapeutics (PTCT) 'Outperform' with a $98 target. GuruFocus values PTCT at $38.71, indicating 71.7% overvaluation. Insiders sold $19.5M in shares. PTCT has a GF Score of 57, showing moderate performance with strengths in momentum but weaknesses in financials.

PTC Therapeutics (PTCT) director Michael Schmertzler sold 20,000 shares worth $1.35m via a 10b5-1 plan, averaging $67.34-$68.67 per share. He still owns 1.32m shares. PTCT stock is down 5% in a week and 13% YTD, deemed overvalued by InvestingPro. The company recently beat Q2 earnings estimates, reporting $0.92 EPS on $361m revenue, and raised full-year guidance. PTCT ended Q2 with $2.23bn in cash.

SCHMERTZLER MICHAEL sold 20,000 indirectly-held shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $67.59 ($67.34–$68.67, $1.35M total) across 3 trades over 2026-09-09 to 2026-09-10 under a Rule 10b5-1 trading plan.